Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 4.235
+0.115 (2.79%)
Sep 30, 2026, 4:08 PM HKT
Lepu Biopharma Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,642 | 8,968 | 4,482 | 6,986 | 12,197 | - | |
Market Cap Growth | -39.59% | 100.10% | -35.85% | -42.72% | - | - |
Enterprise Value | 8,064 | 9,348 | 4,671 | 7,196 | 11,782 | - |
Last Close Price | 4.24 | 4.97 | 2.62 | 4.21 | 7.35 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.76 | 30.83 | - | - | - | - |
PS Ratio | 6.68 | 8.62 | 11.45 | 28.14 | 692.84 | - |
PB Ratio | 4.77 | 5.91 | 6.18 | 7.14 | 11.98 | - |
P/TBV Ratio | 7.99 | 9.10 | 15.74 | 13.71 | 23.98 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.05 | 8.99 | 11.93 | 28.99 | 669.30 | - |
EV/EBITDA Ratio | 83.97 | 79.72 | - | - | - | - |
EV/EBIT Ratio | - | 324.19 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.85 | 0.78 | 1.25 | 0.84 | 0.77 | 0.40 |
Debt / EBITDA Ratio | 13.99 | 8.90 | - | - | - | - |
Net Debt / Equity Ratio | 0.28 | 0.08 | 0.55 | 0.28 | 0.01 | 0.14 |
Net Debt / EBITDA Ratio | 5.57 | 0.99 | -1.19 | -0.81 | -0.02 | -0.14 |
Net Debt / FCF Ratio | -1.70 | -1.80 | -1.63 | -0.89 | -0.02 | -0.14 |
Asset Turnover | 0.36 | 0.35 | 0.16 | 0.09 | 0.01 | - |
Inventory Turnover | 1.81 | 2.40 | 2.87 | 1.06 | 0.08 | - |
Quick Ratio | 1.07 | 0.91 | 0.54 | 0.62 | 0.83 | 0.39 |
Current Ratio | 1.14 | 0.98 | 0.62 | 0.75 | 0.96 | 0.57 |
Return on Equity (ROE) | 24.24% | 25.32% | -54.02% | -3.39% | -80.03% | -87.61% |
Return on Assets (ROA) | -0.09% | 0.60% | -10.61% | -9.94% | -17.41% | -26.18% |
Return on Invested Capital (ROIC) | -0.23% | 2.04% | -36.10% | -38.10% | -68.31% | -98.74% |
Return on Capital Employed (ROCE) | -0.20% | 1.30% | -32.00% | -26.30% | -38.10% | -61.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.73% | 3.24% | -9.77% | -0.35% | -6.39% | - |
FCF Yield | -3.48% | -0.71% | -5.45% | -4.40% | -5.48% | - |
Buyback Yield / Dilution | -5.33% | -3.82% | -1.87% | -1.14% | -7.92% | -33.97% |